Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Keros Therapeutics Inc (NASDAQ: KROS) closed at $14.09 down -6.32% from its previous closing price of $15.04. In other words, the price has decreased by -$6.32 from its previous closing price. On the day, 2.15 million shares were traded. KROS stock price reached its highest trading level at $15.14 during the session, while it also had its lowest trading level at $14.0.
Ratios:
For a deeper understanding of Keros Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.21. For the most recent quarter (mrq), Quick Ratio is recorded 19.29 and its Current Ratio is at 19.29. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On January 17, 2025, Wedbush Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $15.
Oppenheimer reiterated its Outperform rating for the stock on December 16, 2024, while the target price for the stock was revised from $102 to $63.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 09 ’25 when ADAR1 Capital Management, LLC bought 934,258 shares for $10.13 per share. The transaction valued at 9,464,512 led to the insider holds 4,392,737 shares of the business.
GORDON CARL L sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 250,000 shares for $44.01 each. As a result, the insider received 11,002,500 and left with 119,522 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 610856448 and an Enterprise Value of -129856816. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.67 while its Price-to-Book (P/B) ratio in mrq is 0.78. Its current Enterprise Value per Revenue stands at -0.605 whereas that against EBITDA is 14.406.
Stock Price History:
The Beta on a monthly basis for KROS is 1.30, which has changed by -0.7056612 over the last 52 weeks, in comparison to a change of 0.11730647 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $72.37, while it has fallen to a 52-week low of $9.12. The 50-Day Moving Average of the stock is 5.52%, while the 200-Day Moving Average is calculated to be -54.06%.
Shares Statistics:
For the past three months, KROS has traded an average of 959.52K shares per day and 730240 over the past ten days. A total of 40.56M shares are outstanding, with a floating share count of 33.51M. Insiders hold about 17.50% of the company’s shares, while institutions hold 89.34% stake in the company. Shares short for KROS as of 1747267200 were 5772258 with a Short Ratio of 6.02, compared to 1744675200 on 4407820. Therefore, it implies a Short% of Shares Outstanding of 5772258 and a Short% of Float of 22.27.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
